First AD

Second AD

Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer 

Video content above is prompted by the following:

lease describe the role of the multidisciplinary team in the management of treatment-resistant adverse effects for your patients who are receiving antibody-drug conjugates.

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer 

Insights

UCSF Helen Diller Family Comprehensive Cancer Center

Cancer Centers

Partner

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.